Practice and costs of red blood cell (RBC) transfusion in an oncological unit

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 459-464

  Norum, Jan ^a,b   Moen, Mari Ann N ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anemia; Cancer; Cost effectiveness; Erythrocyte transfusion

Indexed keywords

ERYTHROPOIETIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEOPLASM; NORWAY; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROCYTE TRANSFUSION; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NEOPLASMS; NORWAY;

EID: 40549103108     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mughal T: Anemia in patients with cancer. In: Anemia in Cancer, Vol. 6. Ludwig H (ed.). Amsterdam, Elsevier Science, pp. 15-23, 2001.
2. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL and Cella D: American Society of Clinical Oncology. American Society of Hematology (2002). Use of epoetin in patients with cancer: evidence based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107, 2002.
3. Ludwig H, Barrett-Lee PJ, Gascon P, Schneider M and Van Belle S: European Cancer Anemia Survey (eECAS) defines factors surrounding anemia in thousands cancer patients. Proc Am Soc Clin Oncol 21: 387a (abstract 1546), 2002.
4. Barrett-Lee PJ, Bailey NP, O'Brien ME and Wagner E: Large scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93-97, 2000.
5. Tas F, Eralp Y, Basaran M, Sakar B, Alici S and Argon A: Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25: 371-379, 2002.
6. Waters JS, O'Brien ME and Ashley S: Management of anaemia in patients receiving chemotherapy. J Clin Oncol 20: 601-602, 2002.
7. Casadevall N: Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin Oncol 25: (Suppl 7): 12-18, 1998.
8. Coiffier B: Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL). Eur J Cancer 35(Suppl 4): S331 (abstract 1331), 1999.
9. Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M and De Dosso S: Treatment of cancer-related anemia with epoetin alfa: A review. Cancer Treat Rev 30: 563-575, 2004.
10. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwartzer G and Sandercock J: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708-714, 2006.
11. The National Health Administration: The tariff of public outpatient treatment valid from January 1st 2006. Oslo, the National Health Administration, 2005.
12. Department of Health and Care Services: Information about Diagnosis-related Groups 2006. Oslo, Department of Health and Care Services, 2006.
13. Kavanagh BD, Fisher BA, Segreti EM, Wheelock JB, Boardman C and Roseff SD: Cost analysis of erythropoietin versus blood transfusion for cervical cancer patients receiving chemotherapy. Int J Rad Biol Phys 31: 435-441, 2001.
14. Marchetti M and Barosi G: Clinical and economic impact of epoetins in cancer care. Pharm Econ 22: 1029-1045, 2004.
15. Sandler SG, Mallory D, Malamut D and Eckrich R: IgA anaphylactic transfusion reactions. Transfus Med Rev 9: 1-8, 1995.
16. Lai SY and Grandis JR: Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol 24: 4675-4676, 2006.
17. Hardee M, Arcasoy M, Blackwell K, Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339, 2006.
18. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S and Manikhas G: Maintaining normal hemoglobulin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first line chemotherapy. A survival study. J Clin Oncol 23: 5960-6972, 2005.
19. Barosi G, Marchetti M and Liberate NL: Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anemia. Br J Cancer 78: 781-787, 1998.
20. Berudt E, Kallich J, McDermott A, Xu X, Lee H and Glaspy J: Reduction in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharm Econ 23: 505-514, 2005.
21. Crèmieux PY, Finkelstein SN, Berndt ER, Crawford J and Slavin MB: Cost-effectiveness quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anemia. Pharm Econ 16: 459-472, 1999.
22. Meadowcroft A, Gilbert C, Maravich-May D and Hayward S: Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health-Syst Pharm 55: 1898-1902, 1998.
23. Ortega A, Dranitsaris G and Puodziunas AL: What are cancer patients willing to pay for prophylactic epoetin alfa? A cost benefit analysis. Cancer 83: 2588-2596, 1998.
24. Sheffield R, Sullivan S, Saltiel E and Nishimura L: Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15-22, 1997.
25. Hedenus M, Adriansson M, San Miguel J, Kramer MHH, Schipperus MR and Juvonen B: Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomised double-blind, placebo-controlled study. Br J Haematology 122: 394-403, 2003.
26. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB and Musil J: Aranesp 980297 Study Group. Double-blind, placebo controlled, randomized phase III trial of darboepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220, 2002.